Home » Stocks » ENLV

Enlivex Therapeutics Ltd. (ENLV)

Stock Price: $10.49 USD 0.20 (1.94%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $10.21 -0.28 (-2.67%) Jan 15, 7:47 PM
Market Cap 141.24M
Revenue (ttm) n/a
Net Income (ttm) -9.38M
Shares Out 8.65M
EPS (ttm) -0.74
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $10.49
Previous Close $10.29
Change ($) 0.20
Change (%) 1.94%
Day's Open 10.23
Day's Range 10.15 - 10.55
Day's Volume 61,505
52-Week Range 3.77 - 14.50

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 5 days ago

Nes Ziona, Israel, Jan. 11, 2021 (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced ...

GlobeNewsWire - 3 weeks ago

– Comparison of 10 AllocetraTM-treated patients with 37 matched controls showed significant positive responses in state of organ failure, duration of ICU stay and mortality in a highly fragile...

GlobeNewsWire - 1 month ago

Nes Ziona, Israel, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported positive interim results of...

GlobeNewsWire - 1 month ago

* Significant short and long-term clinical improvement for a hospitalized patient with a rare disease that currently has no effective treatment options *

GlobeNewsWire - 1 month ago

* Dr. Schwartz Served as ArQule's Chief Medical Officer and Head of Research and Development Prior to the $2.7 billion Acquisition of ArQule by Merck in February 2020 *

GlobeNewsWire - 2 months ago

Nes Ziona, Israel, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today announced that it will present the c...

GlobeNewsWire - 2 months ago

Nes-Ziona, Israel, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today announced that the U.S. Patent and T...

Zacks Investment Research - 2 months ago

Investors will be keen on pipeline updates when Enlivex Therapeutics (ENLV) reports results for the three months ending Sep 30, 2020.

GlobeNewsWire - 2 months ago

Nes Ziona, Israel, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported that the Israeli Ministry o...

GlobeNewsWire - 2 months ago

Nes Ziona, Israel, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported that the first two patients...

GlobeNewsWire - 3 months ago

Nes Ziona, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported that the Israeli Ministry o...

Benzinga - 3 months ago

Shares of Enlivex Therapeutics Ltd (NASDAQ: ENLV) broke out of a $4-$6 trading range last week and have been seeing strong upward momentum ever since.  A Rally On COVID-19 Data: The catalyst b...

InvestorPlace - 3 months ago

Enlivex just announced that it will launch Phase 2 trials for a plasma-based coronavirus treatment, and ENLV stock is soaring in response. The post ENLV Stock: Why Enlivex Is Soaring 70% Today...

GlobeNewsWire - 3 months ago

Nes Ziona, Israel, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported positive top-line results o...

GlobeNewsWire - 4 months ago

Nes-Ziona, Israel, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, today announced that the China National Intellectual Property Adminis...

GlobeNewsWire - 4 months ago

Nes-Ziona, Israel, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, today announced that the U.S. Patent and Trademark Office  issued a no...

GlobeNewsWire - 5 months ago

- D ata show a 90% decrease in mortality with AllocetraTM treatment in a murine cecal ligation and puncture severe sepsis model

GlobeNewsWire - 6 months ago

Nes-Ziona, Israel, June 18, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Japan Patent Office (JPO) has issued a notic...

GlobeNewsWire - 7 months ago

Nes Ziona, Israel, June 01, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that management will present a corporat...

GlobeNewsWire - 8 months ago

Nes Ziona, Israel, May 07, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that an investigator-initiated multi-cen...

GlobeNewsWire - 9 months ago

Nes Ziona, Israel, April 13, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that the Israel Innovation Authority ...

GlobeNewsWire - 9 months ago

– Final Analysis Comparing 10 AllocetraTM-Treated Patients with 37 Matched Controls Showed Significant Positive Responses in State of Organ Failure, ICU Hospitalization and Mortality in a High...

GlobeNewsWire - 10 months ago

Nes-Ziona, March 09, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Israel Patent Office granted a new patent (#239236)...

GlobeNewsWire - 10 months ago

Nes-Ziona, Israel, March 05, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced the closing of its previously announce...

GlobeNewsWire - 10 months ago

Regarding Submission of Proposal to the Korean Authorities for Potential Use of Allocetra TM  as Treatment of Patients with Coronavirus Disease (COVID-19) Patients Admitted to ICU

GlobeNewsWire - 10 months ago

Nes-Ziona, Israel, March 02, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that it has entered into definitive ag...

GlobeNewsWire - 10 months ago

Nes-Ziona, Israel, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced the closing of its previously announced...

GlobeNewsWire - 10 months ago

Nes-Ziona, Israel, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that it has entered into definitive agr...

Market Watch - 10 months ago

Shares of Israel-based Enlivex Therapeutics Ltd. ENLV, +4.90% rocketed 53% in active premarket trading Monday, after the clinical-stage immunotherapy company said it has started a plan to incr...

GlobeNewsWire - 10 months ago

Nes-Ziona, Israel, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that it is initiating a plan to increa...

GlobeNewsWire - 10 months ago

Nes-Ziona, Israel, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that the company was selected, for a s...

About ENLV

Enlivex Therapeutics, a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. Its product candidate is Allocetra, an immunotherapy candidate, which is in Phase IIb clinical trial in patients with severe sepsis; that is in investigator-initiated Phase II clinical trial for the treatment of COVID-19 patients in severe and critical conditions; and which is in Phase IIa clinical trial for the prevention of Graft Versus Host Disease in allogeneic hematopoietic stem cell transplants (HSCT) patient... [Read more...]

Industry
Biotechnology
IPO Date
Dec 12, 1995
CEO
Oren Hershkovitz
Employees
36
Stock Exchange
NASDAQ
Ticker Symbol
ENLV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for ENLV stock is "Buy" and the 12-month stock price forecast is 22.00.

Price Target
$22.00
Analyst Consensus: Buy